Labopharm Inc. (fka DDSSF)

[maytepper]

Labopharm (DDSS) - Significantly undervalued stock


Tridural - No. 1 Selling in Canada

"Most proud of Tridural, which was licensed from Labopharm. The pain treatment is the No. 1 extended release tramadol drug in Canada, with a 47% market share, compared with a tramadol drug made by Biovail, which has a 30% share", CEO Jonathan Goodman (Paladin Labs), says in an exclusive interview with BioTuesday.ca.


OLEPTRO™ Launched in the U.S. Market

OLEPTRO™, a novel once-daily formulation of the antidepressant trazodone, was launched in the U.S. by Angelini Labopharm, Labopharm's joint venture with Gruppo Angelini. "We are encouraged by the positive early trends in feedback and use of OLEPTRO™ since launch and continue to believe that OLEPTRO™ is a valued option in the treatment of depression." said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc


Canadian Regulatory Decision on Once-Daily Antidepressant Anticipated

Labopharm anticipates a decision on its New Drug Submission (NDS) for once-daily trazodone to be rendered everyday now by Health Canada.


Twice-Daily Tramadol/Acetaminophen Product Approved in Europe

Labopharm's twice-daily tramadol/acetaminophen received a positive opinion under the European Union Decentralized Procedure (DCP) in eight countries (Czech Republic, Iceland, Ireland, Poland, Portugal, Slovakia, Slovenia and Spain). Marketing Authorization (MA) will be granted in each country subject to the approval of translations of the Summary of Product Characteristics (SPC) and other labeling documents. Labopharm is working with its marketing partner, Grünenthal GmbH, towards launching the product in multiple European markets late next year.


Established Marketing Partnership for Twice-Daily Tramadol/Acetaminophen Product in Africa

Subsequent to the end of the third quarter, Labopharm established an exclusive distribution and supply agreement for its twice-daily tramadol/acetaminophen with Paladin Labs Inc. for 13 countries in Sub-Saharan Africa, including South Africa.


Commercialization of Differentiated Products Using Three Technology Platforms

"As we move forward, we continue to focus on the development and commercialization of differentiated products using our three technology platforms - our proven CONTRAMID(R) platform, our promising abuse- and misuse-deterrent platform, INTELLITAB(TM), and our PNDS(TM) platform for the optimized delivery of water-insoluble drugs and, potentially, short interfering ribonucleic acid (siRNA), a rapidly emerging area of drug delivery." said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc.


Established First Marketing Partnerships for INTELLITAB™-Based Product

Also subsequent to the end of the third quarter, Labopharm established exclusive distribution and supply agreements for Canada and 13 Sub-Saharan African countries, including South Africa, with Paladin Labs Inc. for its misuse deterrent and tamper resistant INTELLITAB™ formulation of oxycodone/acetaminophen. The agreements are the first marketing partnerships for Labopharm's INTELLITAB™ technology platform.


Labopharm Monetizes Royalty Stream From Purdue for Ryzolt(TM)

"The monetization of the future expected royalty payments from RYZOLT(TM) provides Labopharm with additional liquidity as we commercialize new products such as OLEPTRO(TM) and twice-daily tramadol-acetaminophen," said James R. Howard-Tripp, President and Chief Executive Officer of Labopharm Inc.


Share Price : 0.93$

DDSS Is the best choice for short and long term on these levels without a doubt.

Look also for Investor Presentation January 2011:

http://www.labopharm.com/docs/Investor%2...

Good Luck!